STOCK TITAN
  1. Home
  2. News
  3. RAPT

RAPT Therapeutics Inc - RAPT STOCK NEWS

Welcome to our dedicated news page for RAPT Therapeutics (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on RAPT Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RAPT Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RAPT Therapeutics's position in the market.

News
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Rhea-AI Summary
RAPT Therapeutics, Inc. announces positive safety and efficacy data from Phase 2 trial of tivumecirnon in combination with pembrolizumab for advanced head and neck squamous cell carcinoma. The study showed a confirmed objective response rate of 15.6% in all patients, 17.4% in PD-L1+ patients, and 22.2% in HPV+ patients, with a median duration of treatment in responders of 19.6 months. The combination treatment was well-tolerated with no increased toxicity observed, demonstrating promise in various oncology indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
clinical trial
-
News
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
RAPT Therapeutics Inc. reports financial results for Q4 and year ended December 31, 2023, with a net loss of $30.9 million in Q4 and $116.8 million for the year. The company maintains a solid cash position of $158.9 million. RAPT is focused on lifting the clinical hold on Phase 2 trials of zelnecirnon in atopic dermatitis and asthma while continuing the Phase 2 study of tivumecirnon in cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
earnings
-
News
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
RAPT Therapeutics, Inc. announces the acceptance of three late-breaking abstracts for poster presentation, including phase 2 clinical data for tivumecirnon in head and neck squamous cell carcinoma at the AACR Annual Meeting in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
conferences
News
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
Rhea-AI Summary
RAPT Therapeutics, Inc. announces FDA clinical hold on Phase 2b trial of zelnecirnon for atopic dermatitis due to serious adverse event of liver failure. Dosing halted in both atopic dermatitis and asthma trials. Investigation ongoing. No liver toxicity in other trial participants. Webcast conference call scheduled for more information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-73.55%
Tags
none
-
News
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
Rhea-AI Summary
RAPT Therapeutics, Inc. appoints Nipun Davar, Ph.D., as Senior Vice President of Technical Operations. Nipun brings over 27 years of biopharmaceutical experience and will aid in advancing zelnecirnon and tivumecirnon in late-stage clinical trials for inflammatory diseases and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
management
-
News
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
RAPT Therapeutics, Inc. (RAPT), a clinical-stage biotech company, will have its CEO participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The discussion will be available via live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
conferences
News
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
RAPT Therapeutics, Inc. (Nasdaq: RAPT) to present company overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
conferences
-
News
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
Rhea-AI Summary
RAPT Therapeutics, a clinical-stage, immunology-based biopharmaceutical company (Nasdaq: RAPT), announced the publication of Phase 1a/1b clinical trial results of zelnecirnon in Allergy. The findings demonstrated positive clinical and molecular effects in patients with moderate-to-severe atopic dermatitis, with significant improvements in key efficacy measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
clinical trial
-
News
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
RAPT Therapeutics, Inc. (Nasdaq: RAPT) maintains a strong cash position of $184.8 million. The company reported a net loss of $31.4 million for the third quarter of 2023, with research and development expenses increasing due to higher development costs related to zelnecirnon and early-stage programs. General and administrative expenses also saw an increase, with a cash balance expected to support operations through mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
earnings
News
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
Rhea-AI Summary
RAPT Therapeutics announces positive safety and efficacy data from its Phase 2 trial of FLX475 in patients with advanced non-small cell lung cancer (NSCLC). The combination of FLX475 and pembrolizumab showed a confirmed objective response rate (ORR) of 40% in PD-L1 positive patients and a median progression-free survival (PFS) of 6.3 months. The ORR for the combination in PD-L1 low and high subsets were 38% and 50% respectively. The data were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.08%
Tags
clinical trial
Stock RAPT logo
RAPT Therapeutics Inc

Nasdaq:RAPT

RAPT Rankings

#3495 Ranked by Market Cap
#4619 Ranked by Stock Gains
N/A Ranked by Dividends

RAPT Stock Data

319.81M
27.51M
1.81%
102.32%
8.55%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About RAPT

rapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively. the company is also pursuing a range of targets that are in the discovery stage of development.